First ‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

ConclusionsThe results indicated that afatnib resulted in significantly better OS and PFS than gefitnib and erlotinib forEGFR mutation ‐positive advanced NSCLC patients without brain metastases.Key pointsSignificant findings of the studyAfatnib resulted in significantly better overall survival and progression ‐free survival than gefitnib and erlotinib forEGFR mutation ‐positive advanced non‐small cell lung cancer patients without brain metastases.What this study addsThis study helps fill the gap in our limited understanding of the differences in the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR ‐TKI), afatinib, with that of reversible EGFR‐TKIs.

Source: Thoracic Cancer - December 18, 2020 Category: Cancer & Oncology Authors: Po ‐Lan Su, Chian‐Wei Chen, Yi‐Lin Wu, Chien‐Chung Lin, Wu‐Chou Su Tags: ORIGINAL ARTICLE Source Type: research